This feature examines the recent rise of colistin use in multidrug-resistant infections and puts it in perspective of its historical use in terms of its safety and tolerability profile. In addition, limitations of using colistin as a first-line agent due to risk of colistin resistance and cases of pandrug resistance are discussed.
RybakM.J.Resistance to antimicrobial agents: an update. Pharmacotherapy.2004; 24(12 pt 2): 203S–215S.
2.
EvansM.E., FeolaD.J., RappR.P.Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother.1999; 33(9): 960–967.
3.
National Nosocomial Infections Surveillance System.National nosocomial infections surveillance (NNIS) system report, data summary from January through June 1992, issued August 2003. Am J Infect Control.2003; 31(8): 481–498.
4.
LeeS.Y., KutiJ.L., NicolauD.P.Polymyxins: older antibiotics for a new threat. Conn Med.2006; 70(1): 25–28.
5.
RiceL.B.Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis.2006; 43(Suppl 2): S100–S105.
6.
HermsenE.D., SullivanC.J., RotschaferJ.C.Polymyxins: pharmacology, pharmacokinetics, pharmacodynamics, and clinical applications. Infect Dis Clin North Am.2003; 17(3): 545–562.
7.
FalagasM.E., KasiakouS.K.Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care.2006; 10(1): R27.
8.
FalagasM.E., BliziotisI.A., KasiakouS.K., SamonisG., AthanassopoulouP., MichalopoulosA.Outcome of infections due to pandrug-resistant (PDR) gram-negative bacteria. BMC Infect Dis.2005; 5(1): 24.
9.
ObritschM.D., FishD.N., MacLarenR., JungR.Nosocomial infections due to multidrug-resistant Pseudomonas Aeruginosa: epidemiology and treatment options. Pharmacotherapy.2005; 25(10): 1353–1364.
10.
GalesA.C., JonesR.N., SaderH.S.Global assessment of the antimicrobial activity of polymyxin B against 54,731 clinical isolates of gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004). Clin Microbiol Infect.2006; 12(4): 315–321.
11.
Coly-Mycin M [package insert].Rochester, MI: Monarch; 2006.
12.
KayeD.Current use for old antibacterial agents: polymyxins, rifampin, and aminoglycosides. Infect Dis Clin North Am.2004; 18: 669–689.
13.
FalagasM.E., KasiakouS.K.Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis.2005; 40: 1333–1341.
14.
LiJ., NationR.L., MilneR.W., TurnridgeJ.D., CoulthardK.Evaluation of col-istin as an agent against multiresistant gram negative bacteria. Int J Antimicrob Agents.2005; 25: 11–25.
15.
ScheetzM.H., HurtK.H., NoskinG.A., OliphantC.M.Applying antimicrobial pharmacodynamics to resistant gram-negative pathogens. Am J Health Syst Pharm.2006; 63: 1346–1360.
16.
GalesA.C., ReisA.O., JonesR.N.Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J Clin Microbiol.2001; 39(1): 183–190.
17.
Clinical and Laboratory Standards Institute.Performance Standards for Antimicrobial Susceptibility Testing: Sixteenth Informational Supplement M100-S16.2006. Wayne, PA.
18.
KarlowskyJ.A., DraghiD.C., JonesM.E., ThornsberryC., FriedlandI.R., SahmD.F.Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001. Antimicrob Agents Chemother.2003; 47(5): 1681–1688.
19.
JainR., DanzigerL.H.Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians. Ann Pharmacother.2004; 38: 1449–1459.
20.
WisplinghoffH., EdmondM.B., PfallerM.A., JonesR.N., WenzelR.P., SeifertH.Nosocomial bloodstream infections caused by Acinetobacter species in United States hospitals: clinical features, molecular epidemiology, and antimicrobial susceptibility. Clin Infect Dis.2000; 31(3): 690–697.
21.
MarkouN., ApostolakosH., KoumoudiouC.. Intravenous col-istin in the treatment of sepsis from multiresistant gram-negative bacilli in critically ill patients. Crit Care.2003; 7(5): R78–R83. http://ccforum.com/content/7/5/R78. Accessed October 10, 2007.
22.
LevinA.S., BaroneA.A., PencoJ.. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis.1999; 28: 1008–1011.
23.
LindenP.K., KusneS., ColeyK., FontesP., KramerD.J., PatersonD.Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin Infect Dis.2003; 37: e154–e160.
24.
Garnacho-MonteroJ., Ortiz-LeybaC., Jimenez-JimenezF.J.. Treatment of multidrug-resistant Acinetobacter baumannii ventilator associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis.2003; 36: 1111–1118.
25.
BerlanaB., LlopJ.M., FortE., BadianM.B., JódarR.Use of colistin in the treatment of multiple-drug resistant gram-negative infections. Am J Health Syst Pharm.2005; 62: 39–47.
26.
MichalopoulosA.S., TsiodrasS., RellosK., MentzelpoulosS., FalagasM.E.Colistin treatment in patients with ICU-acquired infection caused by multi-resistant gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbol Infect.2005; 11(2) 115–121.
27.
FalagasM.E., RizosM., BliziotisI.A., RellosK., KasiakouS.K., MichalopoulosA.Toxicity after prolonged (more than four weeks) administration of intravenous colistin. BMC Infect Dis.2005; 5(1): 1.
Food and Drug Administration.MedWatch Adverse Event Reporting System (March 2004 to December 2006). http://www.fda.gov/cder/aersextract.htm. Accessed April 3, 2007.
30.
FalagasM.E., KasiakouS.K.Use of international units when dosing colistin will help decrease confusion related to various formulations of the drug around the world. Antimicrob Agents Chemother.2006; 50(6): 2274–2275.
31.
DentonM., KerrK., MooneyL.. Transmission of colistin-resistant Pseudomonas aeruginosa between patients attending a pediatric cystic fibrosis center. Pediatr Pulmonol.2002; 34(4): 257–261.
32.
ThiolasA., BolletC., La ScolaB., RaoultD, PagésJ.M.Successive emergence of Enterobacter aerogenes strains resistant to imipenem and colistin in a patient. Antimicrobial Agents and Chemotherapy.2005; 49(4): 1354–1358.
